SEC Form 4 · accession 0001836662-26-000005
Arcus Biosciences, Inc. · RCUS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Carolyn C. Tang
Officer — General Counsel
Period of report
Jun 11, 2026
Accepted (ET)
Jun 12, 2026 · 4:28 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001724521
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jun 11, 2026 | M | 34,090 | $2.574 | A | 184,607 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $2.574 | Jun 11, 2026 | M | 34,090 | D | — | Aug 30, 2027 | Common Stock | 34,090 | 0 | D |
Explanation of responses
- F1Includes 1,783 shares purchased on May 31, 2026 through the Company's Employee Stock Purchase Plan.
- F2Includes the unvested portion of the Reporting Person's RSU grants.
- F3The option is fully vested and has been completely exercised.